REG - Redx Pharma plc - New Grant of Share Options

Redx PharmaAnnouncement

28/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220128:nRSb9085Za&default-theme=true

RNS Number : 9085Z  Redx Pharma plc  28 January 2022

REDX PHARMA PLC

("Redx" or "the Company")

 

New Grant of Share Options

 

 

Alderley Park, UK, 28 January 2022 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, highly targeted therapeutics for the treatment of cancer and
fibrotic disease, announces the grant of share options to certain Directors
and new staff of the Company under the Redx Directors Share Option Scheme (as
adopted on 30 June 2021) and the All Employee Share Option Scheme (as adopted
on 1 July 2020) respectively.

 

The options are being granted with an exercise price of 81 pence per share,
being the closing price on 27 January 2022.

 

The Board has authorised the award of options to the following Directors and
PDMR on 28 January 2022:

 

 Name               Position                          Number of Options  Vesting Date      Total Options following the grant
 Dr Jane Griffiths  Chair and Non-Executive Director  133,333            28 January 2023   400,000

 (Director/PDMR)                                      133,333            28 January 2024

                                                      133,334            28 January 2025

 Dr Rob Scott       Non-Executive Director            66,667             28 January 2023   200,000

 (Director/PDMR)                                      66,667             28 January 2024

                                                      66,666             28 January 2025

 Claire Solk        General Counsel                   166,667            28 January 2023   500,000

 (PDMR)                                               166,667            28 January 2024

                                                      166,666            28 January 2025

 

In addition, options over 1,000,000 ordinary shares of 1p each have been
granted on 28 January 2022 to certain new staff of the company on similar
terms to those above.

 

Following the grants referred to above, the Company will have granted options
over a total of 35,060,437 Ordinary Shares representing 12.7 per cent. of the
current total issued share capital. The number of options that may be awarded
remains limited such that the aggregate number of Ordinary Shares of 1p each
under option will be less than 15 per cent. of the total issued share capital
of the Company.

 

 For further information, please contact:

 Redx Pharma Plc                                T: +44 (0)1625 469 918

 UK Headquarters

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)    T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                 T: +44 (0)203 705 9330
 Claes Spång/ David Wilson/Satheesh Nadarajah

 Panmure Gordon (UK) Limited (Joint Broker)     T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                 T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

 

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase
2 programme in November 2021. The Company's selective ROCK2 inhibitor product
candidate, RXC007, is in development for idiopathic pulmonary fibrosis and
commenced a Phase 1 clinical trial in June 2021. Initial results were reported
in October 2021, with full Phase 1 results expected in 2022.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK
inhibitor now in Phase 3 clinical development by Eli Lilly following its
acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting
fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which
AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has
forged collaborations with Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)   Name                                    Dr Jane Griffiths
 2.  Reason for the notification
 a)  Position/status                          Chair and Non-Executive Director
 b)  Initial notification/Amendment           Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     Redx Pharma Plc
 b)  LEI                                      213800HMS4EBXO589Y37
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Options over Ordinary Shares of 1p each
 b)  Identification code                      ISIN: GB00BSNB6S51
 c)  Nature of the transactions               Grant of options under the Redx Directors Share Option Scheme
 d)  Price(s) and volume(s)                   Price: 81 pence per share

                                              Volume: 400,000 shares
 e)  Aggregated information                   As for d) above

     -     Aggregated volume

     -     Price
 f)  Date of the transactions                 28 January 2022
 f)  Place of the transactions                Off-market

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)   Name                                    Dr Rob Scott
 2.  Reason for the notification
 a)  Position/status                          Non-Executive Director
 b)  Initial notification/Amendment           Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     Redx Pharma Plc
 b)  LEI                                      213800HMS4EBXO589Y37
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Options over Ordinary Shares of 1p each
 b)  Identification code                      ISIN: GB00BSNB6S51
 c)  Nature of the transactions               Grant of options under the Redx Directors Share Option Scheme
 d)  Price(s) and volume(s)                   Price: 81 pence per share

                                              Volume: 200,000 shares
 e)  Aggregated information                   As for d) above

     -     Aggregated volume

     -     Price
 f)  Date of the transactions                 28 January 2022
 f)  Place of the transactions                Off-market

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)   Name                                    Claire Solk
 2.  Reason for the notification
 a)  Position/status                          General Counsel
 b)  Initial notification/Amendment           Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     Redx Pharma Plc
 b)  LEI                                      213800HMS4EBXO589Y37
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Options over Ordinary Shares of 1p each
 b)  Identification code                      ISIN: GB00BSNB6S51
 c)  Nature of the transactions               Grant of options under the Redx All Employee Share Option Scheme
 d)  Price(s) and volume(s)                   Price: 81 pence per share

                                              Volume: 500,000 shares
 e)  Aggregated information                   As for d) above

     -     Aggregated volume

     -     Price
 f)  Date of the transactions                 28 January 2022
 f)  Place of the transactions                Off-market

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUBRWRUOUAUAR